

Impact Patients toward Active Lives
Achieve Financial Goals

● Greater than 600,000 patients using Bioventus Products
 ● Revenue \$581M ● EBITDA \$106M

Talent/Cultural Development

- Promote career growth opportunities with at least a 50% internal promotion rate – Q4
- Create a culture focused on our tenets of Learning & Development, and Caring – Q4
 ◇75% of Employees engaged in self directed learning and 75% of employees use their day of giving
- Complete all Compliance training with a minimum of 90% attendance in All sessions – Q4

Drive Organic Growth through Product Development

- StimRouter Plus FDA Clearance and Launch – Q2
- SonaStar Elite FDA submission – Q2
- EPG Go Platform three channel system completion - Q4

Build Greater Market Penetration through R&D and Clinical Data

- BONES expanded claims submission with Scaphoid – Q4
- OsteoAmp enrollment of 40 patients in RCT – Q4
- OsteoAmp Flowable cannula FDA submission –Q3

Achieve Double Digit Growth through Tuck In Acquisitions

- Complete at least one equity investment in high strategic interest target – Q4
- Complete Misonix Integration and on track for synergy target of \$20M - Q4

Expand Globally in High Opportunity Markets

- Durolane China clinical site readiness/regulatory strategy and plan – Q2
- Launch Curavisc in high priority markets – Q1

Quality/Operational Excellence

- 100% of all CAPAs are completed within 30 days or have an action plan within 30 days – Q4
- Complete new Memphis Operations Center plan, build out and transition with no loss of revenue – Q3

